Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Deciding whether to start hormone therapy during the menopause transition, the life phase that's the bookend to puberty and ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

Visit-to-visit variability in lipid levels is associated with an increased risk for heart failure in patients with T2D, ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

A recent study shows that traditional insulin resistance measures such as HOMA-IR are more predictive of insulin resistance ...

In general, there are two main types of cholesterol: Low-Density Lipoprotein (LDL) and High-Density Lipoprotein (HDL) cholesterol. High levels of LDL, also known as 'bad' cholesterol, can lead to ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...